Concepedia

Author

Tatiana Shelekhova

National and Kapodistrian University of AthensORCID

Also Known As

T V Shelekhova, T. Shelekhova, T. V. Shelekhova, T.V. Shelekhova, Tatiana Shelekhova, Tatiana V. Shelekhova, Tatyana V. Shelekhova, Tatyana Vladimirovna Shelekhova, Т. V. Shelekhova, Т.В. Шелехова

59

Publications

2.5K

Citations

13

H-Index

19

Concepts

All Affiliations

National and Kapodistrian University of AthensUniversity Hospital BrnoInstituto de Investigación Biomédica de SalamancaClinica Universidad de NavarraSeoul National University
TS

About

Tatiana Shelekhova is an author at National and Kapodistrian University of Athens specializing in medicine, hematology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

1.3K

2

Health Sciences

4

4

1.3K

3

Engineering

1

1

13

4

Biochemistry

1

1

13

5

Pathology

1

1

430

Tatiana Shelekhova

×

15

Publications

2.5K

Citations

13

H-Index

YearCitations

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo,

New England Journal of Medicine

2017

949

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon,

The Lancet Oncology

2014

781

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé,

The Lancet

2019

430

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Jacob P. Laubach, Fredrik Schjesvold, Mário Mariz,

The Lancet Oncology

2020

67

The impact of <em>ABCB1</em> (rs1045642 and rs4148738) and <em>CES1</em> (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Dmitriy Alekseevich Sychev, Tatiana Shelekhova, Kristina Ryzhikova,

Pharmacogenomics and Personalized Medicine

2018

49

Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.

Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska,

Journal of Clinical Oncology

2011

29

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

María‐Victoria Mateos, Michèle Cavo, Joan Bladé,

Blood

2019

25

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon,

Blood

2011

22

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios Α. Dimopoulos, María‐Victoria Mateos, Michèle Cavo,

Blood

2018

22

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Stefan Knop, María‐Victoria Mateos, Meletios Α. Dimopoulos,

BMC Cancer

2021

21

Page 1